Clinical Trials Browser

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT02359565 2026-03-18

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

NCT03210714 2026-03-18

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Phase 2 Active not recruiting

20 enrolled 10 charts

CNSGastrointestinalGenitourinaryLymphoidMyeloid

Familial ependymoma, Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03213652 2026-03-18

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Phase 2 Active not recruiting

13 enrolled

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03478462 2026-03-18

CLOVER-2

Phase 1 Active not recruiting

30 enrolled

CNSGenitourinaryLymphoidSarcoma

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Glioma, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

Clinical Trials

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

CLOVER-2

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3

99mTc-1-thio-D-glucose SPECT/CT Versus 18F-Fluoroethyl-l-tyrosine PET/CT in Brain Tumor Imaging

PNOC017

IMPACT

PNOC020

Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma

AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients

RNA PRIME

Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG

m-ctDNA

rQNestin

GLIOTARG

Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype

Mind-Body Intervention in Glioma Couples

Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis

[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma

Step Count Monitoring as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Undergoing Radiation Therapy

Simulation-Based Caregiving Skills Training for Family Members of High Grade Glioma Patients